Building the health economics case for Bioelectrix
Bioelectrix is developing a new medical device to actively accelerate wound healing. The technology itself is important, but in wound care, strong technology is not enough. For a solution to be adopted at scale, it must also prove that it reduces the total burden on healthcare systems. That means showing, in a credible and structured […]
Bioelectrix selected for the REACH 2025–26 cohort
Bioelectrix has been selected as one of eight Nordic deep-tech teams in the REACH 2025–26 cohort, a Silicon Valley–based incubator program run by Nordic Innovation House to accelerate the commercialisation of research-driven technologies with global ambition. Why REACH matters for Bioelectrix Building breakthrough medtech starts with strong technology but winning in the market requires much more than […]